Reports Q2 revenue $4.9M, consensus $940,000. “This quarter, we began to reveal our strategy to realize one of the great opportunities presented by radioligands – the use of patient imaging to evaluate how candidate ligands perform in humans before committing substantial time and resources required to run an interventional trial,” said Joe McCann, Ph.D., CEO of POINT Biopharma. “Imaging can quickly reveal ligand properties and expression of a molecular target. By pairing ligand properties with complementary isotope properties, the potential for therapeutic effect can be efficiently evaluated to optimize clinical development decisions. We are committed to leveraging these theranostic principles and making data-driven program investment decisions in pursuit of accelerated development pathways for new targeted radioligand therapies.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
- Point Biopharma Global Inc. (PNT) Q2 Earnings Cheat Sheet
- Point Biopharma, ITM expand global supply agreement for n.c.a. Lutetium-177
- ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
- Point Biopharma assumed with a Buy at Jefferies